7AL0.F Alligator Bioscience AB (publ)
- Market cap
- EUR 357K
- P/E
- -
- P/B
- 0.17x
- ROE
- -305.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 7AL0.F undervalued?
Graham numberThe Graham number of Alligator Bioscience AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alligator Bioscience AB (publ) fundamental analysis
No fundamental analysis for Alligator Bioscience AB (publ) yet.
Alligator Bioscience AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alligator Bioscience AB (publ)
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage …
Full company profileAlligator Bioscience AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alligator Bioscience AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 12.9M | 35.7M | 58.1M | 57.8M | 514K | 316K |
| Operating Income | -143M | -192M | -249M | -190M | -122M | -97.9M |
| EBITDA | - | -181M | -238M | -170M | -5.13M | -53.6M |
| Net Income | -142M | -193M | -249M | -234M | -51.4M | -70.7M |
| EPS | -9.24 | -13 | -8.97 | -7.31 | -0.07 | -0.11 |
| Balance Sheet | ||||||
| Total Assets | 333M | 170M | 118M | 104M | 111M | 89.4M |
| Total Liabilities | 50.9M | 80.5M | 107M | 235M | 104M | 66.2M |
| Shareholders' Equity | 282M | 89.1M | 11.9M | -131M | 6.86M | 23.2M |
| Cash & Short-term Investments | 278M | 97.3M | 66.1M | 64.3M | 62.2M | 41.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -127M | -173M | -189M | -222M | -156M | -95.1M |
| Capital Expenditure | 45.0K | 440K | 2.46M | 0.00 | 1.46M | 0.00 |
| Free Cash Flow | -127M | -173M | -192M | -222M | -157M | -95.1M |
| Ratios | ||||||
| ROE | -50.2% | -217.2% | -2,096.9% | - | -748.7% | -305.3% |
| ROA | -42.5% | -114.0% | -209.9% | -224.2% | -46.4% | -79.1% |
| Net Profit Margin | -1,095.1% | -541.8% | -427.8% | -404.9% | -9,990.3% | -22,385.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alligator Bioscience AB (publ) dividends
Alligator Bioscience AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:1000 on Apr 7, 2025.
Who owns Alligator Bioscience AB (publ)
- Insiders 18.55%
- Institutions 29.91%
- Public & others 51.54%
- Shares outstanding 3.57B
- Free float 626M
Alligator Bioscience AB (publ) company profile
- Company name
- Alligator Bioscience AB (publ)
- Ticker
- 7AL0.F
- ISIN
- SE0024173637
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- Medicon Village, Lund, Sweden, 223 81
- Phone
- 46 4 65 40 82 00
- Website
- alligatorbioscience.se
About Alligator Bioscience AB (publ)
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 2 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers; and HLX22, an antibody that treats metastatic, gastric, and breast cancers, which is in phase 3 clinical trial. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; Henlius Biotech, Inc.; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.
Alligator Bioscience AB (publ) management
5- Mr. Søren Bregenholt Ph.D.Chief Executive Officer · born 1971
- Mr. Johan GileusChief Financial Officer · born 1965
- Ms. Greta EklundInvestor Relations & Communications Manager
- Dr. Tom MooreChief Medical Officer
- Yago Pico de CoanaMedical Science Director